Additional Metadata
Keywords active surveillance, adverse effects, low risk, MRI, overdiagnosis, overtreatment, Prostate cancer, PSA, screening
Persistent URL dx.doi.org/10.1080/14737140.2017.1319767, hdl.handle.net/1765/99434
Journal Expert Review of Anticancer Therapy
Citation
Drost, F.-J.H, & Roobol-Bouts, M.J. (2017). The need for active surveillance for low risk prostate cancer. Expert Review of Anticancer Therapy, 1–3. doi:10.1080/14737140.2017.1319767